

DAFTAR PUSTAKA

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021 May;71(3):209–49.
2. Wang L, Qin W, Huo YJ, Li X, Shi Q, Rasko JEJ, et al. Advances in targeted therapy for malignant lymphoma. Vol. 5, *Signal Transduction and Targeted Therapy*. Springer Nature; 2020.
3. World Health Organization. The World Health Organization Quality of Life (WHOQOL). 2012. <https://www.who.int/publications/i/item/WHO-HISHSI-Rev.2012.03> - Diakses 23 Oktober 2023.
4. Ferlay J EMLFCMMLPMZASIBF. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2020.
5. WHO. Indonesia Source: Globocan 2020. 2021. <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-factsheets.pdf> - Diakses 23 Oktober 2023.
6. Mugnaini EN, Ghosh N. Lymphoma. Vol. 43, *Primary Care - Clinics in Office Practice*. W.B. Saunders; 2016. p. 661–75.
7. Allart-Vorelli P, Porro B, Baguet F, Michel A, Cousson-Gélie F. Haematological cancer and quality of life: A systematic literature review. Vol. 5, *Blood Cancer Journal*. Nature Publishing Group; 2015.
8. Olsen, Aprn-Cns MM, Lefebvre KB, Brassil KJ. *Chemotherapy and Immunotherapy Guidelines Edited By and Recommendations For Practice*.
9. Akhlaghi E, Lehto RH, Torabikhah M, Sharif Nia H, Taheri A, Zaboli E, et al. Chemotherapy use and quality of life in cancer patients at the end of life: An integrative review. Vol. 18, *Health and Quality of Life Outcomes*. BioMed Central Ltd; 2020.
10. Pacetti P, Paganini G, Orlandi M, Mambrini A, Pennucci MC, Del Freato A, et al. Chemotherapy in the last 30 days of life of advanced cancer patients. *Supportive Care in Cancer*. 2015 Nov 30;23(11):3277–80.
11. Chan W lok, Lam K on, Siu W kwan, Yuen K keung. Chemotherapy at end-of-life: an integration of oncology and palliative team. Vol. 24, *Supportive Care in Cancer*. Springer Verlag; 2016. p. 1421–7.
12. Xu RH, Wong ELY, Jin J, Dou Y, Dong D. Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas. *European Journal of Health Economics*. 2020 Dec 1;21(9):1363–73.
13. Fayers P, Bottomley A. Quality of life research within the EORTC-the EORTC QLQ-C30. www.ejconline.com – Diakses 29 Mei 2024.

14. Ariestine DA. Gambaran Kualitas Hidup Pada Penyintas Limfoma Non Hodgkin Usia Lanjut yang Mendapat Kemoterapi dan Faktor-Faktor yang Berhubungan. *Jurnal Kedokteran Universitas Indonesia*. 2020.
15. Elfarianti B. Faktor-Faktor yang Berhubungan dengan Tingkat Kualitas Hidup Penderita Kanker Payudara di RSK Bedah Ropanasuri Padang. *Fakultas Kedokteran Universitas Andalas*. 2019.
16. Erturhan Turk K, Yilmaz M. The Effect on Quality of Life and Body Image of Mastectomy Among Breast Cancer Survivors. *Eur J Breast Health*. 2018 Sep 27;205–10.
17. Mugnaini EN, Ghosh N. *Lymphoma*. Vol. 43, Primary Care - Clinics in Office Practice. W.B. Saunders; 2016. p. 661–75.
18. World Cancer Research Fund International. Global cancer statistics for the most common cancers in the world. 2022. <https://www.wcrf.org/cancer-trends/worldwide-cancer-data/> - Diakses 25 Oktober 2023.
19. National Cancer Institute. *Cancer Stat Facts: Non-Hodgkin Lymphoma*. 2023. <https://seer.cancer.gov/statfacts/html/nhl.html> - Diakses 22 Oktober 2023.
20. American Cancer Society. *Cancer Facts & Figures 2023*. Atlanta: American Cancer Society; 2023.
21. National Cancer Institute. *Cancer Stat Facts: Hodgkin Lymphoma*. 2023. <https://seer.cancer.gov/statfacts/html/hodg.html> - Diakses 23 Oktober 2023.
22. Kumar P, Clark M. *Clinical medicine*. London: Bailliere Tindall; 2017.
23. Campbell TW, Rupley AE. *Hematology*. Philadelphia, PA: Elsevier - Health Science; 2015.
24. Jamil A, Mukkamalla SKR. *Lymphoma*. 2023. <https://europepmc.org/article/nbk/nbk560826#free-full-text> - Diakses 16 September 2023.
25. The Calgary Guide to Understanding Disease. *Hematology - Non-Hodgkin Lymphoma: Pathogenesis and clinical findings*. 2023. <https://calgaryguide.ucalgary.ca/non-hodgkin-lymphoma-pathogenesis-andclinical-findings/> - Diakses 24 Oktober 2023.
26. The Calgary Guide to Understanding Disease. *Hematology - Hodgkin Lymphoma: Pathogenesis and Clinical Findings*. 2023. <https://calgaryguide.ucalgary.ca/hodgkin-lymphoma---pathogenesis-andclinical-findings/> - Diakses 24 Oktober 2023.
27. Setiati S, Alwi Idrus, Setiyohadi B, Sudoyo W, Syam F, et al. *Buku Ajar Ilmu Penyakit dalam*. Interna Publishing ; 2023.
28. Hoffman R. *Hematology: Basic principles and practice*. Philadelphia, PA: Elsevier; 2023.

29. Satou A, Takahara T, Nakamura S. An Update on the Pathology and Molecular Features of Hodgkin Lymphoma. Vol. 14, *Cancers*. MDPI; 2022.
30. Mey U, Hitz F, Lohri A, Pederiva S, Taverna C, Tzankov A, et al. Diagnosis and treatment of diffuse large B-cell lymphoma. Vol. 142, *Swiss Medical Weekly*. SMW supporting association; 2012.
31. Randall C, Fedoriw Y. Pathology and diagnosis of follicular lymphoma and related entities. Vol. 52, *Pathology*. Elsevier B.V.; 2020. p. 30–9.
32. Weledji EP, Ngowe MN, Abba JS. Burkitt's lymphoma masquerading as appendicitis - two case reports and review of the literature. *World J Surg Oncol*. 2014 Jun 18;12(1).
33. PDQ Adult Treatment Editorial Board. Non-Hodgkin Lymphoma Treatment (PDQ®): Patient Version. PDQ Cancer Information Summaries. 2002. <http://www.ncbi.nlm.nih.gov/pubmed/26389337> - Diakses 24 Oktober 2023.
34. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification. Vol. 32, *Journal of Clinical Oncology*. American Society of Clinical Oncology; 2014. p. 3059–67.
35. National Cancer Institute. SEER Cancer Statistics Review (CSR) 1975-2014. 2018.
36. Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): An open-label, randomised, non-inferiority trial. *The Lancet*. 2015;385(9976):1418–27.
37. Eich HT, Diehl V, Gørgen H, Pabst T, Markova J, Debus J, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the german hodgkin study group HD11 trial. *Journal of Clinical Oncology*. 2010 Sep 20;28(27):4199–206.
38. Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, et al. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. *Br J Haematol*. 2015 Nov 1;171(4):530–8.
39. Sapkota S, Shaikh H. Non-Hodgkin Lymphoma. 2023.
40. Cuccaro A, Bartolomei F, Cupelli E, Galli E, Giachelia M, Hohaus S. Prognostic factors in Hodgkin lymphoma. *Mediterr J Hematol Infect Dis*. 2014;6(1):1–10.
41. Thomas TS, Luo S, Reagan PM, Keller JW, Sanfilippo KM, Carson KR. Advancing age and the risk of bleomycin pulmonary toxicity in a largely

- older cohort of patients with newly diagnosed Hodgkin Lymphoma. *J Geriatr Oncol*. 2020 Jan 1;11(1):69–74.
42. Zhang A, Chen X, Li Z, Ruan M, Zhang YC, Zhu X. Acute myeloid leukemia arising after Hodgkin lymphoma in a patient with WHIM syndrome. Vol. 66, *Pediatric Blood and Cancer*. John Wiley and Sons Inc.; 2019.
 43. Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. International prognostic score in advanced-stage Hodgkin's lymphoma: Altered utility in the modern era. *Journal of Clinical Oncology*. 2012 Sep 20;30(27):3383–8.
 44. Lim KJ, Di Ciaccio P, Hamad N, Polizzotto MN, Milliken S, Cochrane T, et al. Real-World Outcomes of Aggressive B-Cell Non-Hodgkin Lymphoma in People Living with HIV (PLWH) Treated in Australia: An Australasian Lymphoma Alliance Study. *Blood*. 2021 Nov 5;138(Supplement 1):1456–1456.
 45. Kahn JM, Ozuah NW, Dunleavy K, Henderson TO, Kelly K, LaCasce A. Adolescent and young adult lymphoma: Collaborative efforts toward optimizing care and improving outcomes. Vol. 1, *Blood Advances*. American Society of Hematology; 2017. p. 1945–58.
 46. Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. *CA Cancer J Clin*. 2018 Mar;68(2):116–32.
 47. American Cancer Society. Treating Non-Hodgkin Lymphoma. 2018 <https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/treating.html> - Diakses 30 Oktober 2023.
 48. AUSTRALIAN WHOQOL-100, WHOQOL-BREF and CA-WHOQOL INSTRUMENTS User's Manual and Interpretation Guide. 2000.
 49. Evelyn P. Evaluasi Kualitas Hidup Pasien Adolenscent Idiopathic Scoliosis Post-Op Menggunakan Instrumen SF 36 DI RS Wahidin Sudirohusodo Periode Januari 2017 – Desember 2019. *SELL Journal*. 2020;5.
 50. Cai T, Verze P, Bjerklund Johansen TE. The Quality of Life Definition: Where Are We Going? *Uro*. 2021 Feb 25;1(1):14–22.
 51. Endarti AT. Kualitas Hidup Kesehatan: Konsep, Model, dan Penggunaan. *J Ilmu Kesehatan*. 2015;7(2):97–108.
 52. Sibeoni J, Picard C, Orri M, Labey M, Bousquet G, Verneuil L, et al. Patients' quality of life during active cancer treatment: A qualitative study. *BMC Cancer*. 2018 Oct 4;18(1).
 53. Perwitasari DA, Atthobari J, Dwiprahasto I, Hakimi M, Gelderblom H, Putter H, et al. Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia. *Jpn J Clin Oncol*. 2011 Apr;41(4):519–29.
 54. Husson O, de Rooij BH, Kieffer J, Oerlemans S, Mols F, Aaronson NK, et al. The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival

- of Patients with Cancer in the “Real-World”: Results from the Population-Based PROFILES Registry. *Oncologist*. 2020 Apr 1;25(4):e722–32.
55. Sonang S, Purba AT, Pardede FOI. Pengelompokan Jumlah Penduduk Berdasarkan Kategori Usia dengan Metode K-Means. *Jurnal Teknik Informasi dan Komputer (Tekinkom)*. 2019 Dec 30;2(2):166.
 56. Wade Carole, Carol Tavis. *Psikologi* edisi kesembilan jilid 2. 9th ed. Vol. 424. 2007. <https://inlislite.uin-suska.ac.id/opac/detail-opac?id=14180> – Diakses 2 November 2023.
 57. Rahman A, Asri S, Fitriyani A. Pengertian Pendidikan, Ilmu Pendidikan dan Unsur-Unsur Pendidikan. *Al Urwatul Wutsqa: Kajian Pendidikan Islam*. 2022 Jun;
 58. KBBI. Kamus Besar Bahasa Indonesia (KBBI). 2023. <http://kamusbahasaIndonesia.org/pekerjaan> - Diakses 2 November 2023.
 59. KBBI. Kamus Besar Bahasa Indonesia (KBBI). 2023. <https://kbbi.web.id/stadium> - Diakses 2 November 2023.
 60. Radkiewicz C, Bruchfeld JB, Weibull CE, Jeppesen ML, Frederiksen H, Lambe M, et al. Sex differences in lymphoma incidence and mortality by subtype: A population-based study. *Am J Hematol*. 2023 Jan 1;98(1):23–30.
 61. Sutrisno H, Dharmayuda TG, Rena RA. Gambaran Kualitas Hidup Pasien Kanker Limfoma Non Hodgkin yang Dirawat di RSUP Sanglah Denpasar. *Fakultas Kedokteran Universitas Udayana*. 2010.
 62. Klein SL, Flanagan KL. Sex differences in immune responses. Vol. 16, *Nature Reviews Immunology*. Nature Publishing Group; 2016. p. 626–38.
 63. Lansigan F, Barak I, Pitcher B, Jung SH, Cheson BD, Czuczman M, et al. The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. *Cancer Med*. 2019 Jan 1;8(1):165–73.
 64. Asmara I. Penanda Biologis Limfoma Maligna. *Jurnal Kedokteran Unram*. 2018.
 65. Mozaheb Z. Epidemiology of hodgkin’s lymphoma. *Health N Hav*. 2013;05(05):17–22.
 66. Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, et al. Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: Estimates from the 2017 Global Burden of Disease study. *J Hematol Oncol*. 2019 Oct 22;12(1).
 67. Rass V, Ianosi BA, Zamarian L, Beer R, Sahanic S, Lindner A, et al. Factors associated with impaired quality of life three months after being diagnosed with COVID-19. *Quality of Life Research*. 2022 May 1;31(5):1401–14.

68. Hanifati F. Karakteristik Klinikpatologi Pasien Limfoma Maligna di Bagian /KSM Patologi Anatomi RSUP Dr. Mohammad Hoesin Palembang. Fakultas Kedokteran Universitas Sriwijaya. 2022.
69. Sari Y. Prevalensi dan Karakteristik Penderita Limfoma Maligna Selama 5 Tahun di Bagian Patologi Anatomi RSUP Dr. Mohammad Hoesin Palembang. Fakultas Kedokteran Universitas Sriwijaya. 2012.
70. Extermann M, Leeuwenburgh C, Samiiian L, Sehovic M, Xu J, Cubitt C, et al. Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. *J Geriatr Oncol*. 2017 Jan 1;8(1):69–75.
71. El Kheir DYM, Ibrahim AHM. Epidemiological assessment of distress during chemotherapy: who is affected? *J Taibah Univ Med Sci*. 2019 Oct 1;14(5):448–53.
72. Velikova G, Coens C, Efficace F, Greimel E, Groenvold M, Johnson C, et al. Health-Related Quality of Life in EORTC clinical trials - 30 years of progress from methodological developments to making a real impact on oncology practice. *European Journal of Cancer, Supplement*. 2012 Mar;10(1):141–9.
73. Malouf R, Grimley Evans J. Vitamin B6 for cognition. *Cochrane Database of Systematic Reviews*. 2003.
74. Thong MSY, van Noorden CJF, Steindorf K, Arndt V. Cancer-Related Fatigue: Causes and Current Treatment Options. *Curr Treat Options Oncol*. 2020 Feb 1;21(2).
75. Cherwin CH. Gastrointestinal Symptom Representation in Cancer Symptom Clusters: A Synthesis of the Literature. *Oncol Nurs Forum*. 2012 Mar 1;39(2):157–65.
76. Palesh O, Peppone L, Innominato PF, Janelsins M, Jeong M, Sprod L, et al. Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Vol. 4, *Nature and Science of Sleep*. Dove Medical Press Ltd; 2012. p. 151–62.
77. Patel P, Robinson PD, Wahib N, Cheung P, Wong T, Cabral S, et al. Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis. *Supportive Care in Cancer*. 2022 Nov 12;30(11):8855–69.
78. Piechotta V, Adams A, Haque M, Scheckel B, Kreuzberger N, Monsef I, et al. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. *Cochrane Database of Systematic Reviews*. 2021 Nov 16;2022(1).
79. Putri S, Setiawan E, Saldi SRF, Khoe LC, Sari ER, Megraini A, et al. Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis. *BMC Health Serv Res*. 2022 Dec 25;22(1):553.